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Follicular B helper T (Tfh) cells support high affinity
and long-term antibody responses. Here we found
that within circulating CXCR5+ CD4+ T cells in hu-
mans and mice, the CCR7loPD-1hi subset has a
partial Tfh effector phenotype, whereas CCR7hi
PD-1lo cells have a resting phenotype. The circu-
lating CCR7loPD-1hi subset was indicative of active
Tfh differentiation in lymphoid organs and correlated
with clinical indices in autoimmune diseases. Thus
the CCR7loPD-1hi subset provides a biomarker to
monitor protective antibody responses during infec-
tion or vaccination and pathogenic antibody re-
sponses in autoimmune diseases. Differentiation of
both CCR7hiPD-1lo and CCR7loPD-1hi subsets
required ICOS and BCL6, but not SAP, suggesting
that circulating CXCR5+ helper T cells are primarily
generated before germinal centers. Upon antigen re-
encounter, CCR7loPD-1hi CXCR5+ precursors rapidly
differentiate into mature Tfh cells to promote anti-
body responses. Therefore, circulating CCR7lo
PD-1hi CXCR5+ CD4+ T cells are generated during
active Tfh differentiation and represent a new mech-
anism of immunological early memory.770 Immunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc.INTRODUCTION
Previous studies performed by ourselves and others indepen-
dently characterized a subset of helper T cells, termed follicular
B helper T (Tfh) cells, with a distinct gene expression profile and
a specialized role in facilitating antibody responses (Breitfeld
et al., 2000; Chtanova et al., 2004; Crotty, 2011; Fazilleau
et al., 2009; Kim et al., 2004; Kim et al., 2001; King et al., 2008;
Nurieva et al., 2008; Schaerli et al., 2000; Yu et al., 2009a; Yu
and Vinuesa, 2010a). Without Tfh cells, protective antibody
responses are largely diminished, as evidenced by recurrent in-
fections in patients with primary immunodeficiency due to muta-
tions in inducible costimulator (ICOS) or the signaling adaptor
SLAM-associated protein (SAP), two key molecules for Tfh cell
differentiation (King et al., 2008). Although Tfh cells are essential
for protective antibody responses, excessive or dysregulated
Tfh cells can also result in the generation of autoantibodies
and, subsequently, autoimmune diseases (Craft, 2012; Yu and
Vinuesa, 2010b).
The fundamental role of Tfh cells in humoral immunity has
called forth many studies to understand their role in human in-
fections (Cubas et al., 2013; Feng et al., 2011; Lindqvist et al.,
2012; Pallikkuth et al., 2012), autoimmune diseases (Morita
et al., 2011; Simpson et al., 2010; Zhu et al., 2012), and vaccina-
tion (Bentebibel et al., 2013; Pallikkuth et al., 2012). These
studies mainly focused on human blood samples and clearly
showed a positive correlation between the circulating CXC
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tective antibodies or autoantibodies (Bentebibel et al., 2013;
Morita et al., 2011; Pallikkuth et al., 2012; Simpson et al.,
2010; Zhu et al., 2012). Moreover, circulating CXCR5+ T cells
could be further distinguished according to their coexpression
of T helper 1 (Th1), Th2, or Th17 features that possess distinct
capabilities to support B cell antibody production (Bentebibel
et al., 2013; Morita et al., 2011).
Although there is a consensus that circulating CXCR5+ CD4+
T cells are closely associated with Tfh cells, their ontogeny is
still poorly defined. Also unclear is the important question of
whether circulating cells relate to ongoing or past Tfh re-
sponses (Craft, 2012; Pepper and Jenkins, 2011; Yu and
Vinuesa, 2010a). There is still a lack of a reliable method to
identify active Tfh differentiation. The absence of information
on the ontogeny of circulating CXCR5+ CD4+ T cells also raises
the controversy over the existence of bona fide Tfh cells circu-
lating in blood.
Here, we show that circulating CXCR5+ helper T cells
comprise CCR7hiPD-1lo and CCR7loPD-1hi subsets. In human
blood, CCR7loPD-1hi CXCR5+ helper T cells were transiently
increased after vaccination. Circulating CCR7loPD-1hi CXCR5+
helper T cells in mice phenocopy their human counterpart and
follow nearly identical kinetics during antibody responses. The
generation of both CCR7hiPD-1lo and CCR7loPD-1hi CXCR5+
helper T cells is dependent on the costimulatory receptor ICOS
and the transcription factor B cell lymphoma 6 (BCL6), but not
SAP, suggesting that circulating CXCR5+ helper T cells are pri-
marily generated before entering germinal center (GC). In
in vitro T-B coculture, circulating CCR7loPD-1hi CXCR5+ helper
T cells were the most potent among CD4+ T cell subsets to
induce plamablast or plasma cell differentiation and antibody
production. Upon antigen reexposure in vivo, circulating
CCR7loPD-1hi CXCR5+ helper cells rapidly differentiated into
mature Tfh cells to support GC formation, suggesting their capa-
bility as early memory cells to promote antibody responses.
Together, these findings provide new insights into the ontogeny
of circulating CXCR5+ helper T cells. They reveal that the Tfh pre-
cursor CCR7loPD-1hi CXCR5+ cells in blood correlates with
active Tfh differentiation in secondary lymphoid organs, and
there is little evidence for bona fide Tfh cells in blood. Accord-
ingly, in systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) patients, increased levels of the CCR7loPD-1hi sub-
set correlated with elevated autoantibody profiles and more se-
vere disease activities.
RESULTS
CirculatingAntigen-ExperiencedCXCR5+CD4+Helper T
Cells Are Heterogeneous
To understand the ontogeny of circulating CXCR5+ helper
T cells, this population was investigated more closely. All
CXCR5+ CD4+ T cells have downregulated CD45RA (see Fig-
ure S1A available online) as previously reported (Breitfeld
et al., 2000; Kim et al., 2001; Schaerli et al., 2000; Simpson
et al., 2010), reflecting an antigen-experienced phenotype. Hu-
man circulating effector and memory cells contain discrete pop-
ulations of central memory (Tcm) and effector memory (Tem)
T cells, which are characterized by distinct homing capabilityand effector functions (Sallusto et al., 2004). Tcm cells constitu-
tively express CCR7, whereas Tem cells do not (Sallusto et al.,
2004). The majority of circulating CXCR5+ CD4+ T cells express
CCR7 (Breitfeld et al., 2000; Kim et al., 2001; Schaerli et al.,
2000). However, in contrast to naive CD4+ T cells, which uni-
formly expressed high amounts of CCR7, some of circulating
CXCR5+ CD4+ T cells expressed low amounts of CCR7 (Fig-
ure S1B), suggesting heterogeneity in circulating CXCR5+ helper
T cells. When CCR7 and programmed cell death 1 (PD-1), a
marker for recent antigen exposure (Agata et al., 1996) and
Tfh cells (Crotty, 2011; Haynes et al., 2007; King et al., 2008;
Yu and Vinuesa, 2010a), were combined, CXCR5+ helper
T cells could be further segregated into two populations:
CCR7hiPD-1lo and CCR7loPD-1hi. There was an expansion of
the CCR7loPD-1hi population (1.80% ± 1.30%, p = 0.015) in
individuals 1 week after influenza vaccination (Figure 1A;
Figure 1B).
As in human blood, CCR7hiPD-1lo cells represent the majority
of CXCR5+ T cells in mouse blood under resting conditions (Fig-
ure 1C). When mice were intraperitoneally (i.p.) immunized with
sheep red blood cells (SRBCs), there was a transient increase
of the CCR7loPD-1hi subset 1 week after immunization (Fig-
ure 1C; Figure 1D). In contrast, the CCR7hiPD-1lo subset in total
CD4+ T cells remained unchanged at day 7 but increased at day
14 after the peak of the active differentiation of Tfh cells in the
lymphoid organs (Figure 1C; Figure 1E).
To track antigen-specific cells, naive CD45.2 OT-II CD4+
T cells were transferred into congenic CD45.1 mice immunized
i.p. with ovalbumin (OVA) in alum. Seven days after immuniza-
tion, CXCR5+ OT-II cells in blood were predominantly
CCR7loPD-1hi (Figure 1F; Figure 1G). However, the phenotype
of circulating CXCR5+ OT-II cells gradually drifted and 3 weeks
after immunization, CXCR5+ OT-II cells in blood were essentially
CCR7hiPD-1lo (Figure 1F; Figure 1H). Therefore, in both mouse
and humans, circulating CXCR5+ helper T cells are heteroge-
neous with different phenotypic subsets demonstrating distinct
differentiation kinetics during immune response.
Distinct Phenotype of Circulating CCR7hiPD-1lo and
CCR7loPD-1hi Subsets
Phenotypic analysis of naive CD4+ T cells, the circulating
CCR7hiPD-1lo and CCR7loPD-1hi subsets, as well as Tfh cells
in lymphoid organs, displayed a similar pattern of expression
of all proteins examined between human and mouse cells (Fig-
ure 2). Tfh cells have been reported to express highest amounts
of CXCR5, PD-1, and ICOS and low amounts of CCR7 (Crotty,
2011). CD57 and GL7 are suggested markers for GC Tfh in hu-
mans (Kim et al., 2001; King et al., 2008) and mice (Yusuf
et al., 2010), respectively. The CCR7loPD-1hi subset of circu-
lating CXCR5+ CD4+ T cells in blood expressed all these surface
markers, albeit at intermediate levels (Figure 2A; Figure S2C). Tfh
cells express high amounts of the key Tfh transcription factor
BCL6 (Johnston et al., 2009; Nurieva et al., 2009; Yu et al.,
2009b), as well as SAP, which is indispensible for stable T-B
interaction during Tfh cell differentiation (Cannons et al., 2011;
Qi et al., 2008). BCL6 was not expressed by the CCR7loPD-1hi
subset, although SAP expression in these cells was higher
than in naive cells (Figure 2B; Figure S2D). In contrast, the
CCR7hiPD-1lo subset of circulating CXCR5+ CD4+ T cellsImmunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc. 771
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Figure 1. Circulating CXCR5+ CD4+ T Cells
Are Heterogeneous and Are Composed of
CCR7hiPD-1lo and CCR7loPD-1hi Subsets
(A) PBMCs from healthy individuals 1 or 2 weeks
after seasonal influenza vaccination were
analyzed. FACS plots show CCR7 and PD-1
expression on CXCR5+CD45RA CD4+ T cells
from a representative individual.
(B) Statistics (n = 5) show the change in percentage
of CCR7loPD-1hi within the CXCR5+CD4+ T cells at
indicated time points compared to those before
vaccinations (B.V.).
(C–E) Mice were immunized i.p. with SRBCs and
the blood was analyzed at indicated points. FACS
plots show CCR7 and PD-1 expression on
CXCR5+ CD4+ T cells.
(F–H) CD45.2 naive OT-II cells were i.v. injected
into CD45.1 mice followed by i.p. immunization
with OVA in alum. Blood was analyzed at indicated
time points after immunization. FACS plots show
CCR7 and PD-1 expression on CXCR5+ CD4+
T cells (black represents recipient CD45.1 cells;
red represents donor CD45.2 OT-II cells; statistics
shown for transferred OT-II cells). Data are pre-
sented as mean ± SD. Statistics (n = 5–9) show the
results of individual mice and the average values of
each group are linked by the trend line. N.S., not
significant. See also Figure S1.
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Blood Tfh Early Memory Cells Identify Tfh Activityexpressed none of these Tfh markers (Figures 2A and 2B; Fig-
ures S2C and S2D). Similar to naive CD4+ T cells, CD62L and
IL-7R were highly expressed in this subset, whereas the prolifer-
ation marker Ki-67 was expressed in low amounts (Figure 2C;
Figure S2E).
Cytokines are the major effector molecules of T helper cells,
and their expression was examined in CCR7hiPD-1lo and
CCR7loPD-1hi subsets in either CXCR5+CD45RA or
CXCR5CD45RA CD4+ T cells in blood 1 week after influenza
vaccination. Interferon-g (IFN-g), interleukin-4 (IL-4), and IL-17,
the representative cytokines for Th1, Th2, and Th17 cells, were
predominantly expressed by the CCR7loPD-1hi subset in
CXCR5 cells (Figure 2D). The CCR7loPD-1hi subset in
CXCR5+ cells expressed small amounts of IL-17 and IL-4 and
large amounts of IL-21, a key cytokine secreted by Tfh cells to
support GC responses (Linterman et al., 2010; Nurieva et al.,
2008; Vogelzang et al., 2008; Zotos et al., 2010) (Figure 2E).
This subset also expressed notable amounts of IFN-g (Fig-
ure 2D). Cytokine expression in the CCR7hiPD-1lo subset either
within theCXCR5+ or CXCR5 population was limited (Figure 2D;772 Immunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc.Figure S2E). Thus the CCR7loPD-1hi sub-
set in the circulating CXCR5+ CD4+ T cells
possessed a partial Tfh phenotype as
determined by both surface and intra-
cellular markers and cytokine profiles,
whereas the CCR7hiPD-1lo subset
showed a resting status similar to Tcm
cells.
Human blood CXCR5+ CD4+ T cells
can be divided into different functional
subsets based on the expression of
chemokine receptors CXCR3 andCCR6 (Bentebibel et al., 2013; Morita et al., 2011). CXCR3
and CCR6 expression were therefore examined in blood
1 week after influenza vaccination. As reported previously (Mor-
ita et al., 2011), the expression of CXCR3 and CCR6 in individual
subsets largely correlated with the expression of IFN-g and
IL-17, respectively (Figure 2D; Figure S2F). IFN-g and IL-17
were highly expressed by the CCR7loPD-1hi subset in
CXCR5CD45RA cells (Figure 2D) and so were CXCR3 and
CCR6 (Figure 2F). Notably, high CCR6 but low IL-17 expression
was found in the CCR7hiPD-1lo subset in CXCR5+CD45RA cells
(Figure 2F).
We next asked what drives expression of chemokine recep-
tors on circulating CD4+ T cells and whether the pattern of che-
mokine receptors correlates with Tfh differentiation. Naive
CD45.2 OT-II CD4+ T cells were transferred into congenic
CD45.1 mice immunized i.p. with OVA in either alum or Sigma
Adjuvant System (SAS). Alum induced a Th2-type response,
whereas SAS induced a Th1-type response, as indicated by
high expression of IFN-g and CXCR3 in transferred OT-II cells
in spleens (Figures S2F and S2G). There was a similar Tfh
A B
C
D E
F G
Figure 2. Distinct Phenotype of CCR7hi
PD-1lo and CCR7loPD-1hi Subsets
(A–C) Representative histograms and statistics
(n = 5) show the expression of indicated surface
molecules in individual populations as per gating in
Figures S2A and S2B.
(D–F) Representative histograms and statistics
(n = 5) showing cytokine and chemokine receptor
expression in indicated populations of PBMCs
from individuals after influenza vaccination. Sta-
tistics show the results of individuals and the
average values of each group.
(G) CD45.2 naive OT-II cells were i.v. injected into
CD45.1 mice followed by i.p. immunization with
OVA in alum or Sigma Adjuvant System (SAS).
Representative histograms and statistics (n = 5)
show CXCR3 expression in indicated populations
of PBMCs 7 days after immunization. See also
Figure S2.
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Blood Tfh Early Memory Cells Identify Tfh Activitydifferentiation between the two types of adjuvant (Figure S2H).
Corresponding to the response in the spleens, circulating OT-II
cells in the blood also expressed higher amounts of CXCR3 in
both CXCR5+ and CXCR5 subsets in response to SAS
compared to alum (Figure 2G). Therefore, chemokine receptors
per se reflect the polarization of the immune response for Tfh dif-
ferentiation rather than active Tfh cell differentiation.
Differentiation of Circulating Antigen-Experienced
CXCR5+ CD4+ T Cells Is Dependent on Tfh Pathways
It has been previously reported that the circulating CXCR5+
CD4+ T cells are greatly reduced in ICOS-deficient patients
(Bossaller et al., 2006) and that CXCR5 upregulation is impaired
on CD4+ T cells in BCL6-deficient mice (Yu et al., 2009b).
To examine whether the Tfh differentiation pathway intrinsicallyImmunity 39, 770–781,instructs circulating CXCR5+ CD4+
T cells, we transferred naive CD45.2 OT-
II CD4+ T cells deficient in either ICOS or
BCL6 into congenic CD45.1 Cd28/
mice immunized i.p. with OVA in alum.
Seven days after immunization, all trans-
ferred cells had been stimulated by
antigen and undergone proliferation,
indicated by high expression of CD44
and diluted carboxyfluorescein succini-
midyl ester (data not shown). In mice
that received wild-type (WT) OT-II cells,
about a quarter of the antigen-specific
circulating OT-II cells expressed CXCR5
(Figure 3A). TheseCXCR5+ antigen-expe-
rienced cells accounted for approxi-
mately 2% of total CD4+ T cells
(Figure 3B). Transferred T cells that were
deficient in BCL6 or ICOS were unable
to differentiate into Tfh cells or support
GC formation in spleen (Figures S3A and
S3B). Similarly, Bcl6/ or Icos/
T cells were incapable of differentiating
into CXCR5+ cells in blood (Figure 3A;Figure S3B) although they were able to differentiate into CXCR5
cells, comparable to WT cells (Figure 3C).
Circulating Antigen-Experienced CXCR5+ CD4+ T Cells
Are Generated Primarily prior to GC Reaction
The ICOS-mediated upregulation of BCL6 and CXCR5 and the
subsequent initiation of Tfh differentiation can occur as early
as the second cell division during the interaction of antigen-spe-
cific T cells with dendritic cells (Baumjohann et al., 2011; Choi
et al., 2011; Kerfoot et al., 2011). CXCR5+ CD4+ T cells might
enter the circulation during initial Tfh differentiation, prior to GC
formation or from Tfh cells recently exiting from GC responses,
as suggested by the observation that weeks after immunization,
Tfh cells can downregulate BCL6 expression and gain the poten-
tial to become memory cells (Kitano et al., 2011). When doesOctober 17, 2013 ª2013 Elsevier Inc. 773
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Figure 3. Both CCR7hiPD-1lo and
CCR7loPD-1hi Subsets of CXCR5+ CD4+ T
Cells in Blood Are Primarily Generated
before GCs
CD45.2 naive OT-II WT or BCL6- or ICOS-deficient
cells were i.v. injected into CD45.1 Cd28/ mice
followed by i.p. immunization with OVA in alum.
Blood was analyzed 7 days after immunization.
Representative FACS plots show CXCR5 and
PD-1 expression on CD4+ T cells (A).
Statistical analysis (n = 5) of data from individual
mice and the average value of each group (B
and C).
(D)WT or SAP-deficient micewere immunizedwith
SRBCs and blood was analyzed at indicated time
points. FACS plots show CCR7 and PD-1 on
CXCR5+ CD4+ T cell. Statistics (n = 3) shows the
results of individual mice and the average values of
each group are linked by the trend line. CD45.2
naive OT-II WT or SAP-deficient cells were i.v. in-
jected into CD45.1 Cd28/ mice followed by i.p.
immunization with OVA in alum. Blood was
analyzed 7 days after immunization. Representa-
tive FACS plots show CXCR5 and PD-1 expres-
sion on CD4+ T cells (E).
Statistical analysis (n = 5) of data from individual
mice and the average value of each group (F).
PBMCs from XLP carriers (n = 3) were examined
by FACS. SAP-sufficient or -deficient cells were
identified by intracellular staining (G).
Paired analysis between SAP-sufficient or -defi-
cient cells (H). See also Figure S3.
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Blood Tfh Early Memory Cells Identify Tfh Activitycirculating antigen-experienced CXCR5+ CD4+ T cell differentia-
tion deviate from Tfh differentiation (Craft, 2012; Yu and Vinuesa,
2010a)? To address this question, an ideal approach would be to
measure the circulating CXCR5+ CD4+ T cells in a scenario that
allows steps of early Tfh differentiation but not terminal Tfh differ-
entiation or GC formation. This scenario occurs in Sh2d1a/
mice. Without SAP, Tfh differentiation and GC formation are
severely impaired despite the upregulation of ICOS, BCL6, and
CXCR5 (Choi et al., 2011; Deenick et al., 2010).
When SAP-deficient mice were immunized i.p. with SRBCs,
both CCR7hiPD-1lo and CCR7loPD-1hi subsets of circulating
CXCR5+ CD4+ T cells were formed with kinetics similar to that
of WT mice (Figure 3D). When transferred into Cd28/ mice
immunized i.p. with OVA in alum, SAP-deficient OT-II cells
were able to generate circulating CXCR5+ cells in blood compa-774 Immunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc.rable to those from WT OT-II cells (Fig-
ure 3E; Figure S3F), although few Tfh cells
or GCs formed in the spleens (Figures
S3A and S3B). Sublethally irradiated
mice were reconstituted with mixed
bone marrow from WT and Sh2d1a/
mice in a 50%:50% ratio, and the gener-
ation of circulating CCR7hiPD-1lo and
CCR7loPD-1hi subsets was examined in
this competitive environment. If mature
Tfh cells that have exited from GC
response contribute significantly to circu-
lating CXCR5+ CD4+ T cells, fewer SAP-deficient circulating CXCR5+ CD4+ T cells would be observed.
However, both circulating CCR7hiPD-1lo and CCR7loPD-1hi sub-
sets were present in similar percentages between WT and
Sh2d1a/CD4+ T cells before (Figure S3C) and after immuniza-
tion with SRBCs (Figure S3D).
To testwhether the samemechanismalso operates in humans,
we examined blood from patients diagnosed with X-linked
lymphoproliferative disease (XLP). Due to mutations in the
SH2D1A gene, T cells from these patients lack SAP expression
(Cannons et al., 2011). The percentages of circulating CXCR5+
CD4+ T cells and the CCR7hiPD-1lo and CCR7loPD-1hi subsets
in two XLP subjects fell within the normal ranges of healthy con-
trols (Figures S3E and S3F). The very rare frequency of XLP pa-
tients prevents the examination of a larger cohort.We then exam-
ined female XLP carriers who, due to random X-inactivation,
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Figure 4. Increased Percentages of Circu-
lating CCR7loPD-1hi CXCR5+ CD4+ T Cells
Correlates with an Active Tfh Program
CD45.2 naive OT-II cells were i.v. injected into
CD45.1 mice followed by s.c. immunization with
OVA in alum. Blood (A) and popliteal lymph nodes
(PLN) (B) were analyzed from 3 to 11 days after
immunization. Dot plots show the numbers of
indicated populations at each time points. FACS
plots show CCR7 and PD-1 expression on
CXCR5+ CD4+ T cells in blood from 8- to 12-week-
old sanroque or WT mice (C) or from 15- to 20-
week-old BAFF-Tg or WT mice (D).
(E) CD45.2 naive OT-II cells from sanroque (SR) or
WT mice were i.v. injected into CD45.1 mice then
immunized i.p. with OVA in alum. Blood was
analyzed at indicated time points after immuniza-
tion. Statistics (n = 5) shows the results of
individual mice with average values. See also
Figure S4.
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Blood Tfh Early Memory Cells Identify Tfh Activitycontain both SAP-sufficient and SAP-deficient cells (Figure 3G).
Between SAP-sufficient and -deficient CD4+ T cells within indi-
vidual carriers, there was no significant difference in total circu-
lating CXCR5+ CD4+ T cells, neither in CCR7hiPD-1lo or
CCR7loPD-1hi subsets, although there was a trend of decline of
the CCR7hiPD-1lo subset (Figure 3H). These results support a
model whereby in both mice and humans, CCR7hiPD-1lo and
CCR7loPD-1hi subsets in the circulating CXCR5+ CD4+ T cells
are primarily generated before T cells differentiate into mature
Tfh effector cells and participate in GC responses.
Increased Circulating CCR7loPD-1hi CXCR5+ CD4+ T
Cells Correlate with Active Tfh Program
The occurrence of the CCR7loPD-1hi CXCR5+ CD4+ T cells in
blood correlates with active Tfh cell differentiation in secondary
lymphoid organs (Figure 1) and they share many molecular re-
quirements for differentiation (Figure 3). We then asked whether
the CCR7loPD-1hi subset in blood could be utilized as a qualita-
tive or quantitative measurement of Tfh cell differentiation in sec-
ondary lymphoid organs.
In order to track the kinetics of the differentiation of antigen-
specific CCR7loPD-1hi CXCR5+ CD4+ T cells in blood, CD45.2Immunity 39, 770–781,naive OT-II CD4+ T cells were transferred
into CD45.1 congenic mice immunized
subcutaneously (s.c.) with OVA in alum.
CCR7loPD-1hiCXCR5+ OT-II cells be-
came detectable in the blood 4 days after
immunization, peaked at days 6 and 7,
and then declined (Figure 4A). OT-II Tfh
cells in the draining popliteal lymph nodes
also peaked at days 6 and 7 after immuni-
zation and numbers were maintained
(Figure 4B). These results clearly demon-
strate a strong correlation between the
high percentages of the CCR7loPD-1hi
subset in blood and active Tfh cell differ-
entiation (day 3–7) in the draining second-
ary lymphoid organs.We then examined the correlation between the high percent-
age of CCR7loPD-1hi cells among circulating CXCR5+ CD4+
T cells and active Tfh cell differentiation in the secondary
lymphoid organs of sanroque (SR, Roquinsan/san) mice, a model
for systemic autoimmunity driven by aberrant differentiation of
Tfh cells (Linterman et al., 2009; Vinuesa et al., 2005; Yu et al.,
2007). In sanroquemice, a striking 3-fold increase in the percent-
age of CCR7loPD-1hi cells among total CXCR5+ CD4+ T cells in
blood was observed (Figure 4C). The increase in CCR7loPD-1hi
cell percentages correlated with the amount of autoantibodies
against double-stranded DNA (dsDNA) (Figure S4).
The increase in percentages of circulating CCR7loPD-1hi sub-
set in sanroque mice could be explained by either Tfh differenti-
ation stimulated by autoimmune-induced self-antigen exposure
or an intrinsic bias of CD4+ T cells to differentiate to a Tfh fate. To
address the first possibility, we used another model of systemic
autoimmunity, in which a B cell-activating factor (BAFF) trans-
gene (Tg) drives pathology in a T cell-independent manner
(Mackay and Schneider, 2009). Percentages of CCR7loPD-1hi
cells were not increased in the blood of BAFF-Tg mice (Fig-
ure 4D), despite the presence of self-antigen, autoantibodies,
and other autoimmune indicators (Mackay and Schneider,October 17, 2013 ª2013 Elsevier Inc. 775
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Figure 5. Bona Fide Tfh Cells Are Undetect-
able in Blood
Healthy individuals (n = 5) were vaccinated with
seasonal influenza virus vaccines and blood was
taken 7 days after vaccination. Tonsils were ob-
tained from tonsillectomies. FACS plots show
CXCR5, PD-1, and BCL6 expression in CD4+
T cells (A and B) and CCR7 and PD-1 expression
on cells gated from A (C) or BCL6 in cells gated
from C (D). PBMCs and spleens from 8- to 12-
week-old sanroque mice were analyzed. FACS
plots show CXCR5, PD-1, and BCL6 expression in
CD4+ T cells (E and F) and CCR7 and PD-1
expression on cells gated from E (G) or BCL6 in
cells gated from G (H). Statistics (n = 3–5) shows
the results of individual human or mice with
average values.
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Blood Tfh Early Memory Cells Identify Tfh Activity2009). Conversely, when naive OT-II cells with the Roquinsan/san
mutation were adoptively transferred, higher percentages of the
CCR7loPD-1hi subset than those ofWTOT-II cells were observed
(Figure 4E). These observations indicate that the increase of the
CCR7loPD-1hi subset in blood of sanroquemice reflects sponta-
neous and continuous Tfh differentiation. This observation
further validates the usage of the CCR7loPD-1hi subset in blood
as a marker for active Tfh differentiation in secondary lymphoid
organs.
Bona Fide Tfh Cells Are Undetectable in Blood
The controversy of whether Tfh cells are present in blood (Craft,
2012) can be largely attributed to the ambiguous definition of Tfh
cells (Yu and Vinuesa, 2010a). The most widely accepted pheno-
typic definition of Tfh cells is high expression of PD-1 andCXCR5
together with BCL6 (Yu and Vinuesa, 2010a). Blood from human
subjects 1 week after vaccination contained CD4+ T cells with
detectable CXCR5 and PD-1 expression (Figure 5A). However,
if amounts of CXCR5 and PD-1 expression on Tfh cells are
defined by amount expressed on CD4+ T cells in human tonsils,776 Immunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc.then very few, if any, Tfh cells could be
detected in blood (Figure 5A). Similarly,
T cells expressing BCL6 were absent in
blood (Figure 5B). Furthermore, CD4+
T cells with high amounts of CXCR5 and
PD-1 expression were barely detectable
in 26 patients with SLE and 38 patients
with RA (data not shown). Even in sanro-
que mice, which present a massively
expanded Tfh cell compartment in sec-
ondary lymphoid organ as a result of
spontaneous Tfh differentiation (Vinuesa
et al., 2005), Tfh cells in blood were again
undetected (Figure 5E; Figure S5F).
In both human tonsils and mouse
spleens with active Tfh programs, the
CCR7loPD-1hi subset was readily de-
tected in cells expressing intermediate
amounts of CXCR5 (Figure 5C; Fig-
ure S5G). However, unlike their counter-
parts in blood, 2- to 3-fold increase ofBCL6 expression was observed in CCR7loPD-1hi CXCR5+
CD4+ T cells in secondary lymphoid organs (Figure 5D; Fig-
ure S5H). Tfh cell differentiation is a multistage process (Crotty,
2011), and SAP-mediated stable T cell-B cell interaction
strengthens ICOS signaling and BCL6 expression (Choi et al.,
2011). We have previously shown that the differentiation of circu-
lating CXCR5+ CD4+ T cells requires ICOS and BCL6, but not
SAP (Figure 3). The expression of BCL6 in CXCR5+ CD4+
T cells in secondary lymphoid organs, but not in blood, further
suggests that circulating CXCR5+ CD4+ T cells deviate from
Tfh differentiation before stable T cell-B cell interaction for termi-
nal Tfh differentiation.
Expansion of Circulating CCR7loPD-1hi CXCR5+ CD4+ T
Cells in Patients with Autoimmune Diseases
The percentage of total CXCR5+ Tfh-related cells in blood sam-
ples from healthy controls (HC) and patients with RA or SLE was
similar and ranged from about 5% to 25% (Figure 6A; Fig-
ure S6B). In HC, the CCR7loPD-1hi subset among total
CXCR5+ CD4+ T cells ranged from 9% to 21.5%, regardless of
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Figure 6. Increased Percentages of Circu-
lating CCR7loPD-1hi Cells in Autoimmune
Patients with High Amounts of Autoanti-
bodies and Severe Disease Activity
PBMCs were isolated from healthy controls (HC,
n = 30), RA patients (n = 38), and SLE (n = 26)
patients were analyzed.
(A and B) FACS plots and statistics show the
percentages of CXCR5+ CD4+ T cells.
(C and D) FACS plots and statistics show the
CCR7loPD-1hi subset within CXCR5+CD45RA
CD4+ T cells from two representative individuals in
indicated groups. Patients with CCR7loPD-1hi
percentages higher than HC are labeled in red.
(E) The correlation between the concentration of
anti-dsDNA autoantibodies in serum and the per-
centages of CCR7loPD-1hi cells was examined (left
panel) and the classifications based on low or high
CCR7loPD-1hi prercentages as defined in D (right
panel). The thresholds for moderate and high titers
are shown by green and blue lines, respectively.
The numbers of patients with high titers are indi-
cated in blue.
(F and G) The disease activity scores of individual
SLE or RA patients in the CCR7loPD-1hi low or high
groups are shown.
(H) Distribution of low, medium, or high DAS28
RA patients within CCR7loPD-1hi low or high
groups. Statistics show the results of individuals
with average values. See also Figure S5 and
Table S1.
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Blood Tfh Early Memory Cells Identify Tfh Activityage (Figures S5A and S5B). Notably, several RA patients and
more than half of SLE patients showed an increase in the per-
centage of CCR7loPD-1hi cells to greater than 21.5% (labeled
in red, Figure 6C; Figure S6D). The average percentage of
CCR7loPD-1hi subsets in SLE patients was significantly higher
than those in HC (Figure 6D). The percentage of the
CCR7loPD-1hi subset cells within CXCR5+ CD4+ T cells did not
correlate with either age or duration of disease in SLE patients
(Figures S5C and S5D). However, SLE patients with a higher
percentage of CCR7loPD-1hi cells (>21.5%, high group) also
presentedwith higher amounts of several key diagnostic autoan-
tibodies for SLE, including autoantibodies against dsDNA (Fig-
ure 6E), Smith (Sm), and nucleosome (Figures S5E and S5F)Immunity 39, 770–781,than those with lower CCR7loPD-1hi sub-
set percentages (<21.5%, low group).
Furthermore, all (15/15) SLE patients in
the high group had high amounts of
anti-dsDNA, whereas in the low group,
only a small proportion (2/11) of patients
did (Figure 6E). In addition, patients in
this high group showed higher SLE dis-
ease-activity indexes (SLEDAI) (Bombar-
dier et al., 1992) (Figure 6F). RA patients
with high CCR7loPD-1hi percentages
also had higher disease activity scores
(DAS28) (Prevoo et al., 1995) than those
in theCCR7loPD-1hi low group (Figure 6G)
with all patients in the high CCR7loPD-1hi
group classified as high disease activity(Figure 6H). Whereas total CXCR5+ CD4+ T cells in blood are
not indicative of disease activity, overrepresentation of the
CCR7loPD-1hi subset was associated with higher autoantibody
titer and higher disease activity.
Circulating CCR7loPD-1hi CXCR5+ Tfh Precursor Cells
Promote Antibody Responses
The presence of CXCR5+ CD4+ T cells in blood suggests these
cells are generated from draining secondary lymphoid organs
and travel through nondraining secondary lymphoid organs.
We then asked whether this could represent a mechanism to
enhance Tfh differentiation and antibody response in nondrain-
ing secondary lymphoid organs.October 17, 2013 ª2013 Elsevier Inc. 777
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Figure 7. Circulating CCR7loPD-1hi CXCR5+
Tfh Precursor Cells Promote Antibody Re-
sponses
(A and B) CD45.2 naive OT-II cells were i.v. in-
jected into CD45.1 mice followed by i.p. immuni-
zation with OVA in alum. We sorted 60,000
CXCR5+ OT-II cells from blood of immunized mice
at day 7 or 60,000 naive CD4+ T cells from unim-
munized OT-II mice and adoptively transferred
them into CD45.1 Cd28/ mice, which were
immunized i.p. with OVA in alum. Representative
FACS plots and statistical analysis (n = 3) show Tfh
differentiation and GC formation in spleens.
(C and D) We isolated 20,000–50,000 CD4+ T cells
of indicated subsets from individuals 7 days after
influenza vaccine and cocultured them with
autologous memory B cells at 1:1 ratio for 4 days.
Representative FACS plots and statistics (n = 4)
showing the differentiation of plasmablasts or
plasma cells. The production of total IgG in the
coculture supernatants was shown in (E). The
values displayed in (D) and (E) were normalized to
the CXCR5+CCR7 group, which were set to
100%. We isolated 20,000–50,000 CD4+ T cell of
indicated subsets from SLE patients and cocul-
tured them with autologous memory B cells at 1:1
ratio for 4 days. Statistics (n = 8) showing the
production of total IgG (F) and anti-dsDNA IgG (G).
X5, CXCR5; C7, CCR7. See also Figure S6.
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into CD45.1 congenic mice immunized s.c. with OVA in alum at
the rear foot pad. This immunization led to Tfh differentiation
and GC formation in the draining popliteal lymph node, but not
the nondraining brachial lymph node. Six days after this immuni-
zation, a group of mice (R 1st + F 2nd) was immunized with OVA in
alum at front foot pad as a boost. A control group (F 1st) received
only transferred OT-II cells but without the priming immunization
(Figures S6A and S6B). In the prime and boost group (R 1st + F
2nd), antigen-experienced OT-II cells in brachial lymph nodes
rapidly differentiated into mature Tfh cells upon antigen reexpo-
sure to support fast GC formation 5 days after the boost immu-
nization (Figures S6C and S6D). In contrast, despite stronger
proliferation of naive OT-II cells in brachial lymph nodes of the
control group (F 1st) than antigen-experienced OT-II cells in the778 Immunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc.prime and boost group (R 1st + F 2nd) (Fig-
ure S6B), the differentiation into mature
Tfh cells was slower and there was no
GC formation 5 days after the primary
immunization (Figures S6C and S6D).
This demonstrates an ongoing Tfh differ-
entiation and GC response in the draining
secondary lymphoid organ that could
accelerate the Tfh differentiation and
GC response in the nondraining second-
ary lymphoid organ once antigen is
presented.
Circulating CCR7loPD-1hi CXCR5+ Tfh
precursor cells are generated early in
the antibody response (Figure 1; Figures
S4A and S4B). We next examinedwhether these cells are sufficient to accelerate GC formation.
CD45.2 naive OT-II CD4+ T cells were transferred into CD45.1
congenic mice immunized i.p. with OVA in alum. Seven days
after immunization, circulating CXCR5+OT-II cells were predom-
inantly CCR7loPD-1hi (Figure 1F) and were isolated from blood
and adoptively transferred into CD45.1 Cd28/ mice that
were immunized i.p. with OVA in alum. Five days after cell adop-
tive transfer, the CCR7loPD-1hi CXCR5+ but not the control naive
OT-II cells were able to differentiate into mature Tfh cells (Fig-
ure 7A) and initiate GC formation (Figure 7B), despite stronger
proliferation of naive OT-II cells than the CCR7loPD-1hi
CXCR5+ OT-II cells (Figure S6E). This establishes that circulating
CCR7loPD-1hi CXCR5+ CD4+ T cells can rapidly differentiate into
mature Tfh cells upon antigen reencounter and can accelerate
GC formation.
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CCR7loPD-1hi CXCR5+ CD4+ T cells also exists in human, we
sorted different subsets of circulating CD4+ T cells from the
blood of healthy individuals 1 week after influenza vaccination.
By coculturing with autologous memory B cells, CCR7loPD-1hi
CXCR5+ but not naive CD4+ T cells potently induced
CD27hiCD38hi plasmablast or plasma cell differentiation and to-
tal immunoglobulin G (IgG) production. The helper function of
CCR7loPD-1hi CXCR5+ subset was best among all CD4+ T cell
subsets examined (Figure 7C; Figure S7D). Similar results were
also observed for the production of vaccine-specific IgG (Fig-
ure S6F). We next examined whether circulating CCR7loPD-1hi
CXCR5+ Tfh precursor cells might play a pathogenic role in sup-
porting the production of autoantibodies in SLE patients. Due to
lymphopenia in SLE patients, the number of cells that could be
isolated was limited, and therefore we only compared two sub-
sets: CCR7loPD-1hi and CCR7hiPD-1lo CXCR5+ CD4+ T cells.
When cocultured with autologous memory B cells, the
CCR7loPD-1hi subset was better than the CCR7hiPD-1lo subset
in facilitating the production of both total IgG (Figure 7F) and
IgG specific to dsDNA (Figure 7G). By accelerating GC formation
in vivo and enhancing antibody production in vitro, circulating
CCR7loPD-1hi CXCR5+ Tfh precursor cells demonstrate their
capability to promote antibody response.
DISCUSSION
There is great need for a reliable and fully validated method to
identify an active Tfh program with blood, which is the most
convenient and often the only available clinical sample. Moni-
toring active Tfh programwill provide essential information to un-
derstand protective antibody responses during infection or
vaccination and pathogenic antibody responses in autoimmune
diseases. Here, the phenotypes and kinetics of Tfh cell-related
populations in blood were characterized in detail in both animal
models and human samples. Although bona fide Tfh cells were
undetectable in blood, Tfh-related CXCR5+ CD4+ T cells were
present in blood, ranging from 5% to 25% (Figure 6A). In both
mice and humans, two major subsets were clearly identified
within circulating CXCR5+ CD4+ T cells: the CCR7loPD-1hi sub-
set had a Tfh precursor phenotype, whereas the phenotype of
the CCR7hiPD-1lo subset was characteristic of resting cells (Fig-
ure 2; Figure S2).
Stratification of circulating CXCR5+ CD4+ T cells reveals that
it is the CCR7loPD-1hi subset of circulating CXCR5+ CD4+
T cells that identifies active Tfh differentiation (Figure 4A).
Indeed, a high percentage of CCR7loPD-1hi cells were
observed in Tfh-biased autoimmune sanroque mice (Figure 4C)
and SLE patients with high autoantibody titers and severe dis-
ease activities (Figure 6). This new method represents a signif-
icant advancement in monitoring Tfh differentiation, when
compared to previous approaches (Feng et al., 2011; Lindqvist
et al., 2012; Simpson et al., 2010; Zhu et al., 2012). This new
method also extends our knowledge on the heterogeneity of
circulating CXCR5+ CD4+ T cells. In addition to the previous
report that different subsets with Th1, Th2, or Th17 features
possess discrete capabilities to support B cells to produce
antibodies (Bentebibel et al., 2013; Morita et al., 2011), this cur-
rent study demonstrates that the CCR7loPD-1hi subset but notthe CCR7hiPD-1lo subset correlates with active Tfh differentia-
tion. Therefore, a two-dimensional approach to monitor circu-
lating CXCR5+ CD4+ T cells might be required to understand
both polarization and dynamics of Tfh differentiation in
individuals.
The generation of both CXCR5+ CD4+ T cell subsets is depen-
dent on ICOS and BCL6 but independent of SAP in both mouse
and human (Figure 3), suggesting a model in which both subsets
are primarily generated before GC formation. The ontogeny of
circulating CXCR5+ CD4+ T cells rationalizes the logic that an
increase of CCR7loPD-1hi CXCR5+ Tfh precursor cells in blood
represents an active Tfh differentiation in secondary lymphoid
organs.
CD4+ memory T cells are capable of participating memory
responses (Pepper and Jenkins, 2011). Tfh cells sorted from
lymphoid organs were able to survive over a period of time and
participate in the recall responses (Choi et al., 2013; Hale et al.,
2013; Liu et al., 2012; Lu¨thje et al., 2012). Circulating CXCR5+
CD4+ helper T cells can enhance antibody responses in vitro
(Breitfeld et al., 2000; Chevalier et al., 2011; Schaerli et al.,
2000) and in vivo (Sage et al., 2013). Here, we showed that anti-
gen-experienced blood CCR7loPD-1hiCXCR5+ Tfh precursor
cells circulated to nondraining secondary lymphoid organs and
rapidly differentiated into mature Tfh cells to support fast GC for-
mation upon antigen reencounter (Figure 7; Figures S6A–S6D). In
addition, these Tfh precursor cells were better than other circu-
lating CD4+ T cell subsets to provide B helper function in in vitro
culture (Figure 7; Figure S6F). Tfh precursor cells are generated
primarily in the early phase of the response but are not derived
from Tfh cells in GCs. The ability of Tfh precursors to circulate
to nondraining secondary lymphoid organs suggests a mecha-
nism for the immune system to accelerate antibody responses
in nondraining secondary lymphoid organs when infectious
agents begin to spread systemically, in order to win the race
with fast-replicating pathogens.
Using precursor CCR7loPD-1hiCXCR5+ CD4+ T cells to identify
active Tfh differentiation will meet a long-sought goal to monitor
the activation status of an individual’s Tfh program. The ability to
monitor Tfh cells might lead to new strategies to harness an
individual’s Tfh cell program, paving the way to optimizing vacci-
nation strategies and tailoring diagnosis and treatment of auto-
antibody-mediated diseases.
EXPERIMENTAL PROCEDURES
Mice
Bcl6/, Icos/, Sh2d1a/,Cd28/, OT-II, Sanroque (Roquinsan/san), BAFF-
Tg (BaffTg/Tg), and CD45.1 mice were maintained on a C57BL/6 background
and housed in specific pathogen-free conditions at Monash University or Gar-
van Institute animal facilities. All animal experiments were carried under proto-
cols approved by each institute’s animal ethics committee.
Human Subjects
Detailed information of human samples is provided in Supplemental Informa-
tion. Ethics approvals were obtained from each institute’s human ethics
committee.
PBMC Isolation, Cell Subset Purification, and Culture
Human PBMCs were collected into sodium heparin tubes (BD) and purified by
Ficoll-Paque PLUS (GE healthcare) density gradient centrifugation. Mouse
PBMCs were collected into sodium heparin saline buffer (Pfizer) and purifiedImmunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc. 779
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Blood Tfh Early Memory Cells Identify Tfh Activityby Lympholyte (Cedarlane Labs) density gradient centrifugation. Detailed in-
formation of cell subset purification and culture is provided in Supplemental
Information.
Immunizations
To generate T-dependent antibody responses, we immunized mice i.p. with
2 3 109 SRBC (Veterinary Services, IMVS). For induction of T-dependent re-
sponses after adoptive transfer of OT-II cells, mice were i.v. injected with
3–10 3 104 OVA323–339-specific OT-II CD4+ T cells and immunized i.p. with
50 mg of OVA in alum or Sigma Adjuvant System or s.c. footpad with 25 ug
of OVA in alum.
Flow Cytometry and ELISA
Detailed information is provided in Supplemental Information.
Statistical Analyses
All statistical analyses were carried out with Prism (version 5.0, GraphPad
Software) or SPSS (version 16.0). The data are presented as mean ± SD
or as percentages, where appropriate. For comparisons between two popu-
lations, unpaired two-tailed Student’s t tests were performed. For compari-
sons between SAP-sufficient and SAP-deficient cells, paired two-tailed
Student’s t tests were performed. For correlation analyses, either
Spearman’s r or an r2 value derived from Pearson’s r was calculated and
two-tailed p value was determined in the analysis of correlations. Clinical
characteristics and certain laboratory values between patient groups were
compared with chi-square analysis. p values less than 0.05 were considered
statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.immuni.2013.09.007.
AUTHOR CONTRIBUTIONS
J.H. and L.M.T. helped the experimental design, performedmajor experiments
(J.H. for human experiments and L.M.T for human and mouse experiments),
analyzed the data, and edited the manuscript. Y.A.L and X.H. helped with
the experiments. C.S.M. performed experiments on XLP patient samples.
K.V. and S.R. performed experiments on vaccinated subject samples. N.C.,
G.T.B., and A.K. performed preliminary experiments. Y.D., X.S., W.W., and
C.W. helped to collect data on autoimmune patients. M.C.C. and D.S.R.
helped to collect XLP patient samples. S.G.T., A.V., P.L.S., F.M., R.B.,
C.G.V., and C.R.M. provided important materials and reviewed the manu-
script. Z.L. designed experiments and reviewed themanuscript. D.Y. designed
experiments, performed experiments, analyzed the data, wrote the manu-
script, and supervised the study.
ACKNOWLEDGMENTS
We thank FlowCore, Monash University, and Garvan MLC Flow Cytometry
Facility for cell sorting and providing analytical instruments, Monash and Gar-
van animal facilities for animal husbandry and technical services, Karen Laurie
and Anne Kelso for suggestion on influenza vaccination, Andrew Wei for sug-
gestion on immune response after hematopoietic stem cell transplantation,
and Zdenka Prodanovic (the Tissue Bank Southern Health) for collecting hu-
man tissue samples. This work was funded by National Basic Research
Program of China (973 Program, 2010CB529100) To Z.L. and D.Y. National
Health and Medical Research Council (NHMRC, 1010761), Australian
Research Council (DP110105024), Ramaciotti Foundation and National Natu-
ral Science Foundation of China (NSFC, 81128012) to D.Y., Beijing Natural
Science Foundation (7131015) to Z.L. NSFC (3107088) to J.H., and NHMRC
program to C.R.M., C.G.V., S.G.T., R.B., and F.M. D.Y. is supported by a
NHMRC Fellowship (GNT1011947) and a Monash Fellowship. C.S.M. is
supported by a NHMRC Fellowship. C.G.V. is supported by a Viertel Senior
Medical Research Fellowship. C.R.M. is supported by a NHMRC Australian
Fellowship.780 Immunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc.Received: October 26, 2012
Accepted: September 13, 2013
Published: October 17, 2013
REFERENCES
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H., and
Honjo, T. (1996). Expression of the PD-1 antigen on the surface of stimulated
mouse T and B lymphocytes. Int. Immunol. 8, 765–772.
Baumjohann, D., Okada, T., and Ansel, K.M. (2011). Cutting Edge: Distinct
waves of BCL6 expression during T follicular helper cell development.
J. Immunol. 187, 2089–2092.
Bentebibel, S.E., Lopez, S., Obermoser, G., Schmitt, N., Mueller, C., Harrod,
C., Flano, E., Mejias, A., Albrecht, R.A., Blankenship, D., et al. (2013).
Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody re-
sponses to influenza vaccination. Science translational medicine 5, 176ra132.
Bombardier, C., Gladman, D.D., Urowitz, M.B., Caron, D., and Chang, C.H.;
The Committee on Prognosis Studies in SLE. (1992). Derivation of the
SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 35,
630–640.
Bossaller, L., Burger, J., Draeger, R., Grimbacher, B., Knoth, R., Plebani, A.,
Durandy, A., Baumann, U., Schlesier, M., Welcher, A.A., et al. (2006). ICOS
deficiency is associated with a severe reduction of CXCR5+CD4 germinal
center Th cells. J. Immunol. 177, 4927–4932.
Breitfeld, D., Ohl, L., Kremmer, E., Ellwart, J., Sallusto, F., Lipp, M., and
Fo¨rster, R. (2000). Follicular B helper T cells express CXC chemokine receptor
5, localize to B cell follicles, and support immunoglobulin production. J. Exp.
Med. 192, 1545–1552.
Cannons, J.L., Tangye, S.G., and Schwartzberg, P.L. (2011). SLAM family
receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 29, 665–705.
Chevalier, N., Jarrossay, D., Ho, E., Avery, D.T., Ma, C.S., Yu, D., Sallusto, F.,
Tangye, S.G., and Mackay, C.R. (2011). CXCR5 expressing human central
memory CD4 T cells and their relevance for humoral immune responses.
J. Immunol. 186, 5556–5568.
Choi, Y.S., Kageyama, R., Eto, D., Escobar, T.C., Johnston, R.J., Monticelli, L.,
Lao, C., and Crotty, S. (2011). ICOS receptor instructs T follicular helper cell
versus effector cell differentiation via induction of the transcriptional repressor
Bcl6. Immunity 34, 932–946.
Choi, Y.S., Yang, J.A., Yusuf, I., Johnston, R.J., Greenbaum, J., Peters, B., and
Crotty, S. (2013). Bcl6 expressing follicular helper CD4 T cells are fate
committed early and have the capacity to form memory. J. Immunol. 190,
4014–4026.
Chtanova, T., Tangye, S.G., Newton, R., Frank, N., Hodge, M.R., Rolph, M.S.,
and Mackay, C.R. (2004). T follicular helper cells express a distinctive tran-
scriptional profile, reflecting their role as non-Th1/Th2 effector cells that
provide help for B cells. J. Immunol. 173, 68–78.
Craft, J.E. (2012). Follicular helper T cells in immunity and systemic autoimmu-
nity. Nat Rev Rheumatol 8, 337–347.
Crotty, S. (2011). Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29,
621–663.
Cubas, R.A., Mudd, J.C., Savoye, A.L., Perreau, M., van Grevenynghe, J.,
Metcalf, T., Connick, E., Meditz, A., Freeman, G.J., Abesada-Terk, G., Jr.,
et al. (2013). Inadequate T follicular cell help impairs B cell immunity during
HIV infection. Nat. Med. 19, 494–499.
Deenick, E.K., Chan, A., Ma, C.S., Gatto, D., Schwartzberg, P.L., Brink, R., and
Tangye, S.G. (2010). Follicular helper T cell differentiation requires continuous
antigen presentation that is independent of unique B cell signaling. Immunity
33, 241–253.
Fazilleau, N., Mark, L., McHeyzer-Williams, L.J., andMcHeyzer-Williams, M.G.
(2009). Follicular helper T cells: lineage and location. Immunity 30, 324–335.
Feng, J., Lu, L., Hua, C., Qin, L., Zhao, P., Wang, J., Wang, Y., Li, W., Shi, X.,
and Jiang, Y. (2011). High frequency of CD4+ CXCR5+ TFH cells in patients
with immune-active chronic hepatitis B. PLoS ONE 6, e21698.
Immunity
Blood Tfh Early Memory Cells Identify Tfh ActivityHale, J.S., Youngblood, B., Latner, D.R., Mohammed, A.U., Ye, L., Akondy,
R.S., Wu, T., Iyer, S.S., and Ahmed, R. (2013). Distinct memory CD4+ T cells
with commitment to T follicular helper- and T helper 1-cell lineages are gener-
ated after acute viral infection. Immunity 38, 805–817.
Haynes, N.M., Allen, C.D., Lesley, R., Ansel, K.M., Killeen, N., and Cyster, J.G.
(2007). Role of CXCR5 and CCR7 in follicular Th cell positioning and appear-
ance of a programmed cell death gene-1high germinal center-associated
subpopulation. J. Immunol. 179, 5099–5108.
Johnston, R.J., Poholek, A.C., DiToro, D., Yusuf, I., Eto, D., Barnett, B., Dent,
A.L., Craft, J., and Crotty, S. (2009). Bcl6 and Blimp-1 are reciprocal and
antagonistic regulators of T follicular helper cell differentiation. Science 325,
1006–1010.
Kerfoot, S.M., Yaari, G., Patel, J.R., Johnson, K.L., Gonzalez, D.G., Kleinstein,
S.H., and Haberman, A.M. (2011). Germinal center B cell and T follicular helper
cell development initiates in the interfollicular zone. Immunity 34, 947–960.
Kim, C.H., Rott, L.S., Clark-Lewis, I., Campbell, D.J., Wu, L., and Butcher, E.C.
(2001). Subspecialization of CXCR5+ T cells: B helper activity is focused in a
germinal center-localized subset of CXCR5+ T cells. J. Exp. Med. 193,
1373–1381.
Kim, C.H., Lim, H.W., Kim, J.R., Rott, L., Hillsamer, P., and Butcher, E.C.
(2004). Unique gene expression program of human germinal center T helper
cells. Blood 104, 1952–1960.
King, C., Tangye, S.G., and Mackay, C.R. (2008). T follicular helper (TFH) cells
in normal and dysregulated immune responses. Annu. Rev. Immunol. 26,
741–766.
Kitano, M., Moriyama, S., Ando, Y., Hikida, M., Mori, Y., Kurosaki, T., and
Okada, T. (2011). Bcl6 protein expression shapes pre-germinal center B cell
dynamics and follicular helper T cell heterogeneity. Immunity 34, 961–972.
Lindqvist, M., van Lunzen, J., Soghoian, D.Z., Kuhl, B.D., Ranasinghe, S.,
Kranias, G., Flanders, M.D., Cutler, S., Yudanin, N., Muller, M.I., et al. (2012).
Expansion of HIV-specific T follicular helper cells in chronic HIV infection.
J. Clin. Invest. 122, 3271–3280.
Linterman, M.A., Rigby, R.J., Wong, R.K., Yu, D., Brink, R., Cannons, J.L.,
Schwartzberg, P.L., Cook, M.C., Walters, G.D., and Vinuesa, C.G. (2009).
Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med.
206, 561–576.
Linterman, M.A., Beaton, L., Yu, D., Ramiscal, R.R., Srivastava, M., Hogan,
J.J., Verma, N.K., Smyth, M.J., Rigby, R.J., and Vinuesa, C.G. (2010). IL-21
acts directly on B cells to regulate Bcl-6 expression and germinal center
responses. J. Exp. Med. 207, 353–363.
Liu, X., Yan, X., Zhong, B., Nurieva, R.I., Wang, A., Wang, X., Martin-Orozco,
N., Wang, Y., Chang, S.H., Esplugues, E., et al. (2012). Bcl6 expression spec-
ifies the T follicular helper cell program in vivo. J. Exp. Med. 209, 1841–1852,
S1–S24.
Lu¨thje, K., Kallies, A., Shimohakamada, Y., Belz, G.T., Light, A., Tarlinton,
D.M., and Nutt, S.L. (2012). The development and fate of follicular helper
T cells defined by an IL-21 reporter mouse. Nat. Immunol. 13, 491–498.
Mackay, F., and Schneider, P. (2009). Cracking the BAFF code. Nat. Rev.
Immunol. 9, 491–502.
Morita, R., Schmitt, N., Bentebibel, S.E., Ranganathan, R., Bourdery, L.,
Zurawski, G., Foucat, E., Dullaers, M., Oh, S., Sabzghabaei, N., et al. (2011).
Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells
and contain specific subsets that differentially support antibody secretion.
Immunity 34, 108–121.
Nurieva, R.I., Chung, Y., Hwang, D., Yang, X.O., Kang, H.S., Ma, L., Wang,
Y.H., Watowich, S.S., Jetten, A.M., Tian, Q., and Dong, C. (2008).
Generation of T follicular helper cells is mediated by interleukin-21 but inde-
pendent of T helper 1, 2, or 17 cell lineages. Immunity 29, 138–149.
Nurieva, R.I., Chung, Y., Martinez, G.J., Yang, X.O., Tanaka, S., Matskevitch,
T.D., Wang, Y.H., and Dong, C. (2009). Bcl6 mediates the development of T
follicular helper cells. Science 325, 1001–1005.Pallikkuth, S., Parmigiani, A., Silva, S.Y., George, V.K., Fischl, M., Pahwa, R.,
and Pahwa, S. (2012). Impaired peripheral blood T-follicular helper cell func-
tion in HIV-infected nonresponders to the 2009 H1N1/09 vaccine. Blood
120, 985–993.
Pepper, M., and Jenkins, M.K. (2011). Origins of CD4(+) effector and central
memory T cells. Nat. Immunol. 12, 467–471.
Prevoo, M.L., van ’t Hof, M.A., Kuper, H.H., van Leeuwen, M.A., van de Putte,
L.B., and van Riel, P.L. (1995). Modified disease activity scores that include
twenty-eight-joint counts. Development and validation in a prospective longi-
tudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44–48.
Qi, H., Cannons, J.L., Klauschen, F., Schwartzberg, P.L., and Germain, R.N.
(2008). SAP-controlled T-B cell interactions underlie germinal centre forma-
tion. Nature 455, 764–769.
Sage, P.T., Francisco, L.M., Carman, C.V., and Sharpe, A.H. (2013). The
receptor PD-1 controls follicular regulatory T cells in the lymph nodes and
blood. Nat. Immunol. 14, 152–161.
Sallusto, F., Geginat, J., and Lanzavecchia, A. (2004). Central memory and
effector memory T cell subsets: function, generation, and maintenance.
Annu. Rev. Immunol. 22, 745–763.
Schaerli, P., Willimann, K., Lang, A.B., Lipp, M., Loetscher, P., and Moser, B.
(2000). CXC chemokine receptor 5 expression defines follicular homing T cells
with B cell helper function. J. Exp. Med. 192, 1553–1562.
Simpson, N., Gatenby, P.A., Wilson, A., Malik, S., Fulcher, D.A., Tangye, S.G.,
Manku, H., Vyse, T.J., Roncador, G., Huttley, G.A., et al. (2010). Expansion of
circulating T cells resembling follicular helper T cells is a fixed phenotype that
identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum.
62, 234–244.
Vinuesa, C.G., Cook, M.C., Angelucci, C., Athanasopoulos, V., Rui, L., Hill,
K.M., Yu, D., Domaschenz, H., Whittle, B., Lambe, T., et al. (2005). A RING-
type ubiquitin ligase family member required to repress follicular helper
T cells and autoimmunity. Nature 435, 452–458.
Vogelzang, A., McGuire, H.M., Yu, D., Sprent, J., Mackay, C.R., and King, C.
(2008). A fundamental role for interleukin-21 in the generation of T follicular
helper cells. Immunity 29, 127–137.
Yu, D., and Vinuesa, C.G. (2010a). The elusive identity of T follicular helper
cells. Trends Immunol. 31, 377–383.
Yu, D., and Vinuesa, C.G. (2010b). Multiple checkpoints keep follicular helper
T cells under control to prevent autoimmunity. Cell. Mol. Immunol. 7, 198–203.
Yu, D., Tan, A.H., Hu, X., Athanasopoulos, V., Simpson, N., Silva, D.G., Hutloff,
A., Giles, K.M., Leedman, P.J., Lam, K.P., et al. (2007). Roquin represses auto-
immunity by limiting inducible T-cell co-stimulator messenger RNA. Nature
450, 299–303.
Yu, D., Batten, M., Mackay, C.R., and King, C. (2009a). Lineage specification
and heterogeneity of T follicular helper cells. Curr. Opin. Immunol. 21,
619–625.
Yu, D., Rao, S., Tsai, L.M., Lee, S.K., He, Y., Sutcliffe, E.L., Srivastava, M.,
Linterman, M., Zheng, L., Simpson, N., et al. (2009b). The transcriptional
repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity
31, 457–468.
Yusuf, I., Kageyama, R., Monticelli, L., Johnston, R.J., Ditoro, D., Hansen, K.,
Barnett, B., and Crotty, S. (2010). Germinal center T follicular helper cell IL-4
production is dependent on signaling lymphocytic activation molecule recep-
tor (CD150). J. Immunol. 185, 190–202.
Zhu, C., Ma, J., Liu, Y., Tong, J., Tian, J., Chen, J., Tang, X., Xu, H., Lu, L., and
Wang, S. (2012). Increased frequency of follicular helper T cells in patients with
autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 97, 943–950.
Zotos, D., Coquet, J.M., Zhang, Y., Light, A., D’Costa, K., Kallies, A., Corcoran,
L.M., Godfrey, D.I., Toellner, K.M., Smyth, M.J., et al. (2010). IL-21 regulates
germinal center B cell differentiation and proliferation through a B cell-intrinsic
mechanism. J. Exp. Med. 207, 365–378.Immunity 39, 770–781, October 17, 2013 ª2013 Elsevier Inc. 781
